Literature DB >> 23601492

Induction of toxin-specific neutralizing immunity by molecularly uniform rice-based oral cholera toxin B subunit vaccine without plant-associated sugar modification.

Yoshikazu Yuki1, Mio Mejima, Shiho Kurokawa, Tomoko Hiroiwa, Yuko Takahashi, Daisuke Tokuhara, Tomonori Nochi, Yuko Katakai, Masaharu Kuroda, Natsumi Takeyama, Koji Kashima, Michiyo Abe, Yingju Chen, Ushio Nakanishi, Takehiro Masumura, Yoji Takeuchi, Hiroko Kozuka-Hata, Hiroaki Shibata, Masaaki Oyama, Kunisuke Tanaka, Hiroshi Kiyono.   

Abstract

Plants have been used as expression systems for a number of vaccines. However, the expression of vaccines in plants sometimes results in unexpected modification of the vaccines by N-terminal blocking and sugar-chain attachment. Although MucoRice-CTB was thought to be the first cold-chain-free and unpurified oral vaccine, the molecular heterogeneity of MucoRice-CTB, together with plant-based sugar modifications of the CTB protein, has made it difficult to assess immunological activity of vaccine and yield from rice seed. Using a T-DNA vector driven by a prolamin promoter and a signal peptide added to an overexpression vaccine cassette, we established MucoRice-CTB/Q as a new generation oral cholera vaccine for humans use. We confirmed that MucoRice-CTB/Q produces a single CTB monomer with an Asn to Gln substitution at the 4th glycosylation position. The complete amino acid sequence of MucoRice-CTB/Q was determined by MS/MS analysis and the exact amount of expressed CTB was determined by SDS-PAGE densitometric analysis to be an average of 2.35 mg of CTB/g of seed. To compare the immunogenicity of MucoRice-CTB/Q, which has no plant-based glycosylation modifications, with that of the original MucoRice-CTB/N, which is modified with a plant N-glycan, we orally immunized mice and macaques with the two preparations. Similar levels of CTB-specific systemic IgG and mucosal IgA antibodies with toxin-neutralizing activity were induced in mice and macaques orally immunized with MucoRice-CTB/Q or MucoRice-CTB/N. These results show that the molecular uniformed MucoRice-CTB/Q vaccine without plant N-glycan has potential as a safe and efficacious oral vaccine candidate for human use.
© 2013 Society for Experimental Biology, Association of Applied Biologists and John Wiley & Sons Ltd.

Entities:  

Keywords:  MucoRice-CTB; cholera; cholera toxin; oral vaccine; rice-based vaccine

Mesh:

Substances:

Year:  2013        PMID: 23601492     DOI: 10.1111/pbi.12071

Source DB:  PubMed          Journal:  Plant Biotechnol J        ISSN: 1467-7644            Impact factor:   9.803


  21 in total

1.  RNAi-mediated suppression of endogenous storage proteins leads to a change in localization of overexpressed cholera toxin B-subunit and the allergen protein RAG2 in rice seeds.

Authors:  Shiho Kurokawa; Masaharu Kuroda; Mio Mejima; Rika Nakamura; Yuko Takahashi; Hiroshi Sagara; Natsumi Takeyama; Shigeru Satoh; Hiroshi Kiyono; Reiko Teshima; Takehiro Masumura; Yoshikazu Yuki
Journal:  Plant Cell Rep       Date:  2013-10-02       Impact factor: 4.570

2.  Dengue virus E glycoprotein production in transgenic rice callus.

Authors:  Tae-Geum Kim; Mi-Young Kim; Nguyen-Quang-Duc Tien; Nguyen-Xuan Huy; Moon-Sik Yang
Journal:  Mol Biotechnol       Date:  2014-12       Impact factor: 2.695

Review 3.  Edible plants for oral delivery of biopharmaceuticals.

Authors:  Matilde Merlin; Mario Pezzotti; Linda Avesani
Journal:  Br J Clin Pharmacol       Date:  2016-05-09       Impact factor: 4.335

4.  Development of a novel transgenic rice with hypocholesterolemic activity via high-level accumulation of the α' subunit of soybean β-conglycinin.

Authors:  Cerrone Cabanos; Naoki Kato; Yoshiki Amari; Keigo Fujiwara; Tomoki Ohno; Kousuke Shimizu; Tsuyoshi Goto; Masaya Shimada; Masaharu Kuroda; Taro Masuda; Fumio Takaiwa; Shigeru Utsumi; Satoshi Nagaoka; Nobuyuki Maruyama
Journal:  Transgenic Res       Date:  2014-03-28       Impact factor: 2.788

5.  Rice-based oral antibody fragment prophylaxis and therapy against rotavirus infection.

Authors:  Daisuke Tokuhara; Beatriz Álvarez; Mio Mejima; Tomoko Hiroiwa; Yuko Takahashi; Shiho Kurokawa; Masaharu Kuroda; Masaaki Oyama; Hiroko Kozuka-Hata; Tomonori Nochi; Hiroshi Sagara; Farah Aladin; Harold Marcotte; Leon G J Frenken; Miren Iturriza-Gómara; Hiroshi Kiyono; Lennart Hammarström; Yoshikazu Yuki
Journal:  J Clin Invest       Date:  2013-08-08       Impact factor: 14.808

6.  Good manufacturing practices production of a purification-free oral cholera vaccine expressed in transgenic rice plants.

Authors:  Koji Kashima; Yoshikazu Yuki; Mio Mejima; Shiho Kurokawa; Yuji Suzuki; Satomi Minakawa; Natsumi Takeyama; Yoshiko Fukuyama; Tatsuhiko Azegami; Takeshi Tanimoto; Masaharu Kuroda; Minoru Tamura; Yasuyuki Gomi; Hiroshi Kiyono
Journal:  Plant Cell Rep       Date:  2015-12-11       Impact factor: 4.570

Review 7.  Plant-based vaccines for animals and humans: recent advances in technology and clinical trials.

Authors:  Natsumi Takeyama; Hiroshi Kiyono; Yoshikazu Yuki
Journal:  Ther Adv Vaccines       Date:  2015-09

8.  Compensatory rebalancing of rice prolamins by production of recombinant prolamin/bioactive peptide fusion proteins within ER-derived protein bodies.

Authors:  Fumio Takaiwa; Lijun Yang; Yuhya Wakasa; Kenjiro Ozawa
Journal:  Plant Cell Rep       Date:  2017-10-26       Impact factor: 4.570

9.  Comparative whole-genome analyses of selection marker-free rice-based cholera toxin B-subunit vaccine lines and wild-type lines.

Authors:  Koji Kashima; Mio Mejima; Shiho Kurokawa; Masaharu Kuroda; Hiroshi Kiyono; Yoshikazu Yuki
Journal:  BMC Genomics       Date:  2015-02-05       Impact factor: 3.969

Review 10.  Cholera Toxin Subunit B as Adjuvant--An Accelerator in Protective Immunity and a Break in Autoimmunity.

Authors:  Thomas Stratmann
Journal:  Vaccines (Basel)       Date:  2015-07-24
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.